Yaotang Biotech Secures Over RMB 100 Million in Series A+ Financing to Accelerate In Vivo Gene Editing Therapeutics

VCBeat has learned that,YolTech Therapeutics, a global pioneer in in vivo gene editing and base editing technologies, has recently completed an A+ financing round exceeding RMB 100 million. The round was led by Decheng Capital, with participation from Guangzhou State-owned Development Holding Co., Ltd. and Huafang Capital. HAOYUE CAPITAL served as the exclusive financial advisor for this round. This marks the company’s second fundraising of over RMB 100 million since it closed its A round in August last year, which was led by Yuanyi Investment and joined by Xianfeng Qiyun, Yinglian Health Fund, and Jiuhe Ventures. To date, YolTech Therapeutics has raised nearly RMB 300 million in its Series A financing rounds.

YolTech Therapeutics is a leading enterprise holding foundational patents for CRISPR/Cas and base editing tools on a global scale. The company possesses a high-throughput gene editor evolution platform, a rare capability in China. Currently, its three major technology platforms—Cas enzymes, base editors, and lipid nanoparticles (LNPs)—are all protected by independent intellectual property rights and core patents, ensuring freedom to operate worldwide.

The Company has assembled a team of internationally renowned experts in gene-editing tool development, mRNA-LNP drug process development, and CMC, to rapidly advance the development and clinical translation of in vivo gene-editing therapies mediated by mRNA-LNP delivery systems. It is pursuing a global strategy targeting multiple unmet clinical needs, with a pipeline covering genetic disorders, metabolic diseases, and infectious diseases. CurrentlyYolTech Therapeutics’ First In Vivo Gene-Editing Drug Candidate, YOLT-201, Has Completed Toxicology and Pharmacology Studies, preclinical large-animal studies have preliminarily demonstrated the safety and efficacy of YOLT-201, with in vivo editing efficiency after a single dose achieving best-in-class performance, indicating its potential as a best-in-class therapy. YolTech Therapeutics has recently submitted an Investigational New Drug (IND) application for YOLT-201 to the National Medical Products Administration (NMPA),Poised to Launch China’s First Registered Clinical Trial for an In Vivo Gene Editing Drug Based on mRNA-LNP Delivery。

YolTech Therapeutics is currently dedicated to exploring disease treatment solutions from the very origin of life, with a pipeline covering conditions ranging from rare diseases to common ailments. Its R&D capabilities encompass the entire process, from underlying tool platforms to downstream drug development. Leveraging a clear independent intellectual property strategy to position itself in the global market, while actively expanding external collaborations, YolTech Therapeutics strives to contribute its “one-shot cure” gene therapy solutions to patients worldwide, building an in vivo gene editing drug brand that is “rooted in China and going global.”

Dr. Wu Yuxuan, Founder of YolTech TherapeuticsStatement: We extend our sincere gratitude to both new and existing shareholders for their recognition and support of YolTech Therapeutics and its team. Driven by innovation, YolTech Therapeutics is strategically positioned with globally leading in vivo gene editing technologies. The company focuses on developing next-generation in vivo gene editing therapeutics via mRNA-LNP delivery systems, providing patients with superior treatment options. Our mission is to achieve true industrialization of gene therapy drugs, drive the development of the pharmaceutical industry and innovation in treatment strategies, and develop disruptive “one-and-done” curative therapies for various refractory diseases. Following the completion of this financing round, the company will accelerate clinical studies of its core pipeline while simultaneously advancing multiple global first-in-class programs. We aim to bring hope to patients at an early stage and contribute the “YolTech Solution” to medical progress!

Decheng CapitalDecheng Capital stated that it seeks out global leaders with disruptive innovation capabilities and proprietary technologies, and YolTech Therapeutics represents a significant strategic investment for Decheng in the field of gene editing. YolTech focuses on the clinical application of CRISPR/Cas technology for in vivo gene editing. Leveraging its proprietary protein discovery and evolution platform, it is one of the few Chinese biotechnology companies to have successfully developed single-base deaminases, Cas12 and Cas13 editors, and DNA integrases with global intellectual property rights. Furthermore, the company has successfully developed several cationic lipids applicable to lipid nanoparticles (LNPs) to facilitate the in vivo delivery of gene editing tools. Committed to the clinical translation of its in vivo gene editing technologies, YolTech aims to develop curative therapies for genetic diseases. The founding team brings proven product development experience in the gene therapy sector and has demonstrated remarkable execution capability within just one year of the company’s establishment. Moving forward, Decheng will leverage its extensive layout in the domestic and international gene therapy sectors and their upstream and downstream supply chains, as well as its global industrial and academic network resources, to actively provide post-investment value-added services. This support will help propel YolTech onto the international stage, establishing it as a globally competitive gene editing enterprise.

Wei Dahua, Chairman of Guangzhou Industrial Investment CapitalStatement: The era of gene therapy has arrived, and gene editing technologies have already demonstrated positive therapeutic efficacy in clinical studies. The team at YolTech Therapeutics possesses extensive experience in the development of base editing tools, protein engineering, and LNP delivery, holding a foundational patent portfolio covering multiple Cas enzymes and base editors. This positions the company to develop next-generation in vivo gene editing therapeutics with enhanced efficacy and safety. With capital support from Guangzhou State-owned Development Holding Co., Ltd., there is an expectation that YolTech’s innovative gene therapies will reach the market soon, benefiting patients worldwide.

Luo Wangqian, Partner at Huafang CapitalGene editing is a revolutionary technology in the global biotechnology sector, with its clinical translation advancing rapidly worldwide and demonstrating immense application potential across various clinical indications. As a next-generation gene editing technology, base editing offers significant advantages in terms of safety and precision. YolTech Therapeutics is a leading enterprise in China in the fields of in vivo gene editing and base editing, boasting a world-class R&D team and an industry-leading proprietary technology platform. Its next-generation mRNA-LNP therapeutics will achieve significant cost advantages upon scaled manufacturing. We are highly optimistic about the development prospects of in vivo gene editing and base editing therapies, and we are pleased to join hands with the company’s team and both new and existing investors to drive the advancement of the gene editing industry, aiming to deliver safer, more effective, and more affordable gene therapies to patients in China and around the world at the earliest possible time.

Li Yishi, Senior Partner at HAOYUE CAPITAL"We believe that single-base gene editing technologies will bring new opportunities and hope to patients worldwide who are burdened by diseases but lack effective treatment options. YolTech Therapeutics was co-founded by three leading scientists who have organically integrated and further developed their respective cutting-edge research achievements on the YolTech platform. We are delighted to participate in this critical phase of YolTech’s development and are highly optimistic about the company’s continued exploration and global expansion in the field of in vivo gene editing therapeutics."